 |
| 19-Jun-13 | Reiterated |
Mizuho |
Buy |
$66 → $85 |
|
| 07-Jun-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$65 → $72 |
|
| 13-May-13 | Reiterated |
WallachBeth |
Hold |
$45 → $48 |
|
| 10-May-13 | Reiterated |
UBS |
Neutral |
$54 → $55 |
|
| 10-May-13 | Reiterated |
Mizuho |
Buy |
$60 → $66 |
|
| 01-Mar-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$60 → $63 |
|
| 11-Jan-13 | Initiated |
RBC Capital Mkts |
Outperform |
$53 |
|
| 30-Nov-12 | Initiated |
Mizuho |
Buy |
$60 |
|
| 09-Aug-12 | Upgrade |
Cantor Fitzgerald |
Hold → Buy |
$50 → $60 |
|
| 30-Jul-12 | Downgrade |
Cantor Fitzgerald |
Buy → Hold |
$61 → $59 |
|
| 10-Apr-12 | Downgrade |
Auriga |
Buy → Hold |
|
|
| 28-Feb-12 | Upgrade |
Auriga |
Hold → Buy |
$55 |
|
| 10-Nov-11 | Reiterated |
Brean Murray |
Buy |
$50 → $53 |
|
| 21-Oct-11 | Reiterated |
JMP Securities |
Mkt Outperform |
$48 → $40 |
|
| 30-Sep-11 | Initiated |
Auriga |
Hold |
$30 |
|
| 20-Sep-11 | Reiterated |
UBS |
Neutral |
$40 → $32 |
|
| 06-May-11 | Reiterated |
UBS |
Neutral |
$37 → $39 |
|
| 29-Apr-11 | Initiated |
Brean Murray |
Buy |
$50 |
|
| 25-Feb-11 | Reiterated |
UBS |
Neutral |
$47 → $34 |
|
| 25-Feb-11 | Reiterated |
Stifel Nicolaus |
Buy |
$52 → $45 |
|
|
|
| 18-Jun-13 04:35PM | ViroPharma Up on Takeover Rumors Zacks |
| 04:20PM | AstraZeneca and NGM Collaborate Zacks |
| 09:41AM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online |
| 17-Jun-13 05:00PM | US Launch of Forest's Namenda XR Zacks |
| 02:20PM | XOMA Commences Gevokizumab Study Zacks |
| 13-Jun-13 04:40PM | Update on UCB Lupus Candidate Zacks |
| 04:25PM | FDA Panel Meeting for Salix Drug Zacks |
| 09:32AM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 12-Jun-13 04:40PM | Orphan Drug Status for ViroPharma's Maribavir Zacks |
| 09:40AM | Questcor Surges on Drug Acquisition Zacks |
| 11-Jun-13 05:55PM | AstraZeneca to Buy Pearl Therapeutics Zacks +5.02% |
| 04:05PM | Tentative Approval for SUPN Candidate Zacks |
| 03:29PM | Salix Rises On Unusually High Volume (SLXP) at TheStreet |
| 01:16PM | Analysts: Apple Met WWDC Expectations and 3 More Research Notes to Check Out at Wall St. Cheat Sheet |
| 09:01AM | InPlay: Salix and Progenics (PGNX) announce FDA Advisory Committee to review relistor sNDA for opioid-induced constipation in patients with chronic pain Briefing.com |
| 09:00AM | Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain Business Wire |
| 10-Jun-13 04:25PM | Update on Gentium's Defibrotide Zacks |
| 04:05PM | Encouraging Data on Novartis Candidate Zacks |
| 03:40PM | Pipeline Progress at Roche Zacks |
| 12:16PM | Salix Reaches New 52-Week High (SLXP) at TheStreet |
| 07-Jun-13 05:50PM | Positive Data on Novartis' Afinitor Zacks |
| 04:50PM | BioLineRx Enrolls First Patient in Study Zacks |
| 10:40AM | Pfizer in $635 Million Deal Zacks |
| 06-Jun-13 06:30PM | Impax Reduces Workforce Zacks |
| 06:10PM | Avanir to Expedite AVP-786 Development Zacks |
| 03:00PM | Endo to Trim Workforce Zacks |
| 11:40AM | Priority Review for AZN/BMY Drug Zacks |
| 05-Jun-13 05:15PM | FDA Issues Warning Letter to Novartis Zacks |
| 04:45PM | AstraZeneca to Return Fostamatinib Rights Zacks |
| 04:00PM | Astellas' Launch Plans for Acofide Zacks |
| 09:13AM | The Zacks Analyst Blog Highlights: Eli Lilly, Teva, Salix Pharmaceuticals, Santarus and Turkcell Iletisim Hizmetleri Zacks |
| 04-Jun-13 06:00PM | CHMP Positive on Novartis' Lucentis Zacks |
| 04:20PM | Pipeline Setbacks at Sanofi Zacks |
| 04:15PM | Glaxo/Renaissance Ink Deal Zacks |
| 02:33PM | Eli Lilly's Alimta Disappoints Zacks |
| 01:13PM | Biopharma Company Banking On Flagship Gastrointestinal Drug at Forbes |
| 03-Jun-13 06:05PM | AstraZeneca Presents Olaparib Data Zacks |
| 05:40PM | Novo Nordisk Seeks IDegLira Approval Zacks |
| 04:55PM | Shire Settles Lawsuit with Teva Zacks |
| 04:10PM | Glaxo Reports Votrient Data Zacks |
| 03:05PM | Roche Presents Data on Avastin Zacks |
| 01:24PM | Bull Of The Day: Salix Pharmaceuticals at Seeking Alpha |
| 08:55AM | Zacks Bull and Bear of the Day Highlights: Salix Pharmaceuticals, Integra LifeSciences, Tesla Motors, Nissan Motor and Toyota Motor Zacks |
| 08:30AM | Data on Merck Candidate at ASCO Zacks |
| 31-May-13 06:12PM | GSK/Genmab Report Positive Arzerra Data Zacks |
| 05:15PM | Idenix Pharma Initiates Phase II Study Zacks |
| 03:45PM | Postive Interim Data on Pacira's Exparel Zacks |
| 01:20PM | Salix Stock Hits New 52-Week High (SLXP) at TheStreet |
| 10:12AM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 30-May-13 06:20PM | NICE News for BMY/AstraZeneca Zacks |
| 06:10PM | Glaxo's Oncology Portfolio Gets a Boost Zacks |
| 05:04PM | ANAC's Discussion with FDA for Tavaborole Zacks |
| 03:30PM | Salix Pharmaceuticals to Present at Two Investment Conferences in June Business Wire |
| 02:49PM | 3 Merger and Acquisitions Stock Stories For Due Diligence at Wall St. Cheat Sheet |
| 07:00AM | InPlay: Salix Pharma acquires worldwide rights to Olon's intellectual property relating to Amorphous Rifaximin Briefing.com |
| 07:00AM | Salix Pharmaceuticals Acquires Worldwide Rights to Olons Intellectual Property Relating to Amorphous Rifaximin Business Wire |
| 29-May-13 05:35PM | Dutch Approval for Astellas' Vesomni Zacks |
| 05:10PM | Setback for Valeant Pharma Zacks |
| 03:51PM | Positive Data on Salix's Budesonide Foam Zacks |
| 03:15PM | Encouraging Data from Novartis Zacks |
| 12:00PM | Encouraging Data from Novartis Zacks |
| 28-May-13 07:18PM | Valeant Pharma to Buy Bausch+Lomb Zacks |
| 05:05PM | Mixed News on Merck's Pipeline Zacks |
| 04:15PM | J&J's Promising Pharma Pipeline Zacks |
| 03:35PM | Obesity Data on Novo Nordisk's Victoza Zacks |
| 24-May-13 12:45PM | Salix Stock Hits New 52-Week High (SLXP) at TheStreet |
| 11:05AM | Positive Data from Synergy Pharma Zacks |
| 11:00AM | New Diagnostic Solution from Roche Zacks |
| 09:29AM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 23-May-13 06:20PM | Pfizer Halts Inotuzumab Study Zacks |
| 05:30PM | Data on AstraZeneca's Naloxegol Zacks |
| 05:05PM | Repros to Conduct Phase IIb Trial Zacks |
| 05:04PM | Don't Get Too Worked Up Over Salix Pharmaceuticals's Latest Numbers at Motley Fool |
| 22-May-13 05:15PM | Positive Data on Roche Candidate Zacks |
| 04:30PM | Data on Merck KGaA's L-BLP25 Zacks |
| 04:25PM | Data on UCB's Neupro Zacks |
| 10:40AM | AbbVie Extends Galapagos Deal Zacks |
| 07:01AM | InPlay: Salix Pharma announces statistically significant results for Budesonide foam in the treatment of active mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis in two pivotal phase 3 studies Briefing.com |
| 07:00AM | Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 Studies Business Wire |
| 21-May-13 05:30PM | Positive Data on Novartis' Afinitor Zacks |
| 04:10PM | Positive Data on Novo Nordisk's N9-GP Zacks |
| 04:00PM | Actavis to Buy Warner Chilcott Zacks |
| 10:50AM | JNJ's Simponi Label Expanded Zacks |
| 10:17AM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 20-May-13 11:00AM | FDA Accepts Actavis NDA Zacks |
| 17-May-13 01:04PM | SALIX PHARMACEUTICALS LTD Financials EDGAR Online Financials |
| 07:00AM | Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013 Business Wire |
| 16-May-13 06:00PM | Good News for Roche's Tarceva Zacks |
| 15-May-13 05:16PM | Good News for Novartis' Ilaris Zacks |
| 11:10AM | FDA Accepts Merck BLA Zacks |
| 09:55AM | Salix Stock Hits New 52-Week High (SLXP) at TheStreet |
| 14-May-13 09:45AM | Salix Beats on Earnings Zacks |
| 12-May-13 11:55AM | Investors are Digesting These Healthcare Stock Earnings Insights at Wall St. Cheat Sheet |
| 11-May-13 06:19PM | Salix Pharmaceuticals Ltd. Earnings Call Insights: Fulyzaq and Apriso at Wall St. Cheat Sheet |
| 10-May-13 05:19PM | The Gory Details on Salix Pharmaceuticals's Double Miss at Motley Fool +5.52% |
| 01:58PM | Priceline Is a Buy and 4 More Analyst Opinions To Know Now at Wall St. Cheat Sheet |
| 09-May-13 11:04PM | SALIX PHARMACEUTICALS LTD Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 08:01PM | Salix Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 05:04PM | Salix Pharmaceuticals Earnings: Heres Why Investors are Excited Now at Wall St. Cheat Sheet |
| 05:00PM | Salix Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today CCBN |
|
|
| Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. The company offers XIFAXAN tablets for the treatment of patients with travelers' diarrhea, and for overt hepatic encephalopathy; MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; APRISO for the maintenance of remission of ulcerative colitis; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; and SOLESTA for the treatment of fecal incontinence; DEFLUX for the treatment of vesicoureteral reflux. It also provides FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO for the treatment of mildly to moderately active ulcerative colitis in males; and METOZOLV ODT for the treatment of symptomatic documented gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine Tablets, which are used as adjunct for the prevention of rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL for the treatment of hypertension and also as adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney diseases; and COLAZAL for mildly to moderately active ulcerative colitis. The company was founded in 1989 and is headquartered in Raleigh, North Carolina. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Sirgo Mark A | Director | May 03 | Sale | 54.00 | 2,008 | 108,432 | 31,057 | May 07 05:46 PM | | KEANE WILLIAM P | Director | Apr 15 | Option Exercise | 15.25 | 30,000 | 457,398 | 63,202 | Apr 17 05:06 PM | | KEANE WILLIAM P | Director | Apr 15 | Sale | 49.44 | 30,000 | 1,483,200 | 33,202 | Apr 17 05:06 PM | | Forbes William P | EVP Research&Devel & CDO | Apr 10 | Option Exercise | 17.53 | 13,000 | 227,890 | 80,191 | Apr 12 05:05 PM | | Forbes William P | EVP Research&Devel & CDO | Apr 10 | Sale | 49.37 | 8,673 | 428,186 | 71,518 | Apr 12 05:05 PM | | D ALONZO THOMAS | Director | Apr 08 | Option Exercise | 7.60 | 15,000 | 114,000 | 90,640 | Apr 10 04:25 PM | | D ALONZO THOMAS | Director | Apr 08 | Sale | 49.57 | 6,186 | 306,670 | 84,454 | Apr 10 04:25 PM | | Sirgo Mark A | Director | Mar 20 | Sale | 50.05 | 3,000 | 150,150 | 28,955 | Mar 22 06:40 PM | | Scruggs Rick D | Executive Vice President | Mar 07 | Sale | 49.69 | 2,000 | 99,380 | 48,566 | Mar 08 04:54 PM | | Scruggs Rick D | Executive Vice President | Mar 06 | Sale | 49.34 | 5,000 | 246,700 | 50,566 | Mar 08 04:54 PM | | Sirgo Mark A | Director | Jan 11 | Sale | 46.19 | 3,000 | 138,570 | 31,955 | Jan 15 04:19 PM | | CHAPPELL JOHN F | Director | Jan 03 | Option Exercise | 7.60 | 15,000 | 114,000 | 450,224 | Jan 07 04:38 PM | | DERBYSHIRE ADAM C | EVP Finance/CFO | Dec 26 | Option Exercise | 8.00 | 90,000 | 720,000 | 236,601 | Dec 28 04:38 PM | | DERBYSHIRE ADAM C | EVP Finance/CFO | Dec 26 | Sale | 41.44 | 60,000 | 2,486,382 | 176,601 | Dec 28 04:38 PM | | LOGAN CAROLYN J | President & CEO | Dec 20 | Option Exercise | 7.60 | 33,750 | 256,500 | 660,881 | Dec 21 04:32 PM | | LOGAN CAROLYN J | President & CEO | Dec 20 | Sale | 42.27 | 25,000 | 1,056,673 | 635,881 | Dec 21 04:32 PM | | CHAPPELL JOHN F | Director | Dec 04 | Sale | 42.53 | 3,000 | 127,590 | 435,224 | Dec 06 04:37 PM | | CHAPPELL JOHN F | Director | Nov 21 | Sale | 41.62 | 3,000 | 124,860 | 438,224 | Nov 26 04:22 PM | | CHAPPELL JOHN F | Director | Nov 14 | Sale | 41.15 | 3,000 | 123,450 | 441,224 | Nov 16 04:50 PM | | Sirgo Mark A | Director | Nov 13 | Sale | 40.75 | 1,725 | 70,294 | 34,955 | Nov 13 06:50 PM | | Sirgo Mark A | Director | Nov 12 | Sale | 40.30 | 1,725 | 69,518 | 36,680 | Nov 13 06:50 PM | | LOGAN CAROLYN J | President & CEO | Jun 28 | Option Exercise | 4.07 | 228,467 | 929,861 | 763,788 | Jul 02 05:01 PM | | LOGAN CAROLYN J | President & CEO | Jun 28 | Sale | 52.07 | 119,300 | 6,211,832 | 644,488 | Jul 02 05:01 PM |
|
|
|
|
|
|
